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Objectives The purpose of this study was to evaluate the prognostic importance of novel markers of renal dysfunction
among patients with acutely destabilized heart failure (ADHF).
Background -trace protein (BTP) and cystatin C are newer biomarkers for renal dysfunction; the prognostic importance of
these tests, particularly BTP, relative to standard measures of renal function remains unclear.
Methods A total of 220 consecutive hospitalized patients with ADHF were prospectively studied. Blood samples were col-
lected on presentation. In-hospital worsening renal function, as well as mortality and/or heart failure (HF) hospi-
talization, over a median follow-up period of 500 days was examined as a function of BTP or cystatin C concen-
trations; results were compared with creatinine, estimated glomerular filtration rate, and blood urea nitrogen.
Results Neither BTP nor cystatin C was associated with worsening renal function during the index hospitalization. A total
of 116 patients (53%) either died or were hospitalized for HF during follow-up. Those with adverse outcomes had
higher BTP (1.04 mg/l [range 0.80 to 1.49 mg/l] vs. 0.88 mg/l [range 0.68 to 1.17 mg/l], p  0.003) and cys-
tatin C (1.29 mg/l [range 1.00 to 1.71 mg/l] vs. 1.03 mg/l [range 0.86 to 1.43 mg/l], p  0.001). After multi-
variable adjustment, both BTP (hazard ratio: 1.41, 95% confidence interval: 1.06 to 1.88; p  0.018) and cysta-
tin C (hazard ratio: 1.50, 95% confidence interval: 1.13 to 2.01; p  0.006) were significant predictors of
death/HF hospitalization, whereas serum creatinine, estimated glomerular filtration rate, and blood urea nitro-
gen were no longer significant. In patients with an estimated glomerular filtration rate 60 ml/min/1.73 m2,
elevated concentrations of BTP and cystatin C were still associated with significantly higher risk of adverse clini-
cal events (p  0.05). Net reclassification index analysis suggested cystatin C and BTP deliver comparable infor-
mation regarding prognosis.
Conclusions Among patients hospitalized with ADHF, BTP and cystatin C predict risk of death and/or HF hospitalization and
are superior to standard measures of renal function for this indication. (J Am Coll Cardiol 2011;57:849–58)
© 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.08.644Kidney dysfunction is an exceptionally important adverse
prognostic factor in patients with acutely destabilized heart
failure (ADHF) (1). Accordingly, the identification of
laboratory parameters capable of more accurately assessing
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accepted August 10, 2010.renal function than conventional measures of renal function
(e.g., creatinine, estimated glomerular filtration rate [eGFR]
or blood urea nitrogen [BUN]) may be particularly relevant
for this population. Although prognostically meaningful,
conventional measures of renal function have limitations:
creatinine and BUN levels are affected by several nonre-
nal factors including age, body weight, nutritional status,
and sex; in addition, creatinine, eGFR, and BUN are
generally insensitive for detecting mild chronic kidney
disease (2– 4).
See page 859
Cystatin C, a 13-kDa cysteine protease inhibitor, has
recently emerged as a novel marker of renal function with a
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cular disease, including ADHF
(5–13). -trace protein (BTP) is a
low molecular mass protein be-
longing to the lipocalin protein
family that has been established as
an accurate marker of cerebrospi-
nal fluid leakage (14). Further-
more, it has also been recently
described as a more sensitive
marker than serum creatinine in
detecting impaired renal function,
with performance comparable to
that of cystatin C (15–17). The
prognostic role of plasma BTP in
hospitalized patients with ADHF
has not been previously studied,
and its comparative value to cysta-
in C or conventional measures of renal function in these
atients is not known. Therefore, in this prospective study of
ospitalized patients with ADHF, we aimed to assess the
rognostic value of BTP and cystatin C relative to more
onventional measures of renal function.
ethods
tudy population and design. From September 2006 to
arch 2009, we prospectively enrolled 220 consecutive
atients admitted with an established final diagnosis of
DHF (diagnosed clinically using current guidelines [1]) to
he Department of Cardiology at Virgen de la Arrixaca
niversity Hospital (Murcia, Spain). Blood samples were
ollected for all patients on arrival at the emergency depart-
ent. Baseline clinical characteristics and hospital events
ere prospectively recorded. Echocardiography was also
erformed on all patients before hospital discharge. Left
entricular ejection fraction was measured using Simpson’s
iplane method. All patients received standard heart failure
HF) management, as recommended by contemporary
uidelines (1). During the entire hospitalization period,
linical management decisions about each patient were
ade by the cardiologist responsible, who was unaware of
he patient’s BTP and cystatin C concentrations.
Determination of both BTP and cystatin C levels was
erformed using a BN ProSpec analyzer (Dade Behring
mbH, Liederbach, Germany). The intra-assay and inter-
ssay coefficients of variation for BTP were 2.8% and 4.7%,
espectively. The intra-assay and interassay coefficients of
ariation for cystatin C were 2.5% and 2.0%, respectively.
onventional measures of renal function included serum cre-
tinine, eGFR (calculated using the simplified Modification of
iet in Renal Disease equation: 186.3  plasma creatinine 
.154  age  0.203; the correction factor for women was
.742) (18), and BUN.
ollow-up and clinical end point. We examined worsen-
Abbreviations
and Acronyms
ADHF  acutely
destabilized heart failure
BTP  -trace protein
BUN  blood urea nitrogen
CI  confidence interval
eGFR  estimated
glomerular filtration rate
GFR  glomerular filtration
rate
HF  heart failure
HR  hazard ratio
NT-proBNP  N-terminal
pro–B-type natriuretic
peptideng renal function (defined as a maximum increase in serumreatinine during hospitalization of 0.3 mg/dl [19]) as a
unction of BTP or cystatin C concentrations; results were
ompared with creatinine, eGFR, and BUN. For the
rimary outcome measure as the combination of mortality
nd/or HF hospitalization, all patients were clinically fol-
owed during a median of 500 days (interquartile range 231
o 796). Death was ascertained from available medical
ecords and death certificates. If hospital records were
mbiguous or unavailable, National Death Records were
onsulted. In patients requiring hospitalization, medical
ecords were carefully reviewed to further characterize the
ause of hospitalization. The study was approved by the
ocal ethics committee, and informed consent was obtained
rom each patient at inclusion.
tatistical analysis. Continuous variables were tested for a
ormal distribution by the Kolmogorov-Smirnov test. Nor-
ally distributed data are presented as the mean  SD and
non-normally distributed data as the median (interquartile
range, interquartile data). Categorical variables are ex-
pressed as percentages. Categorized analyses were per-
formed according to the presence of adverse clinical events
during the follow-up. Differences in baseline characteristics
were compared using the Student t test or the Mann-
Whitney U test for continuous variables and the chi-square
test for categorical variables. Relationships between BTP,
cystatin C, and other clinical and analytical parameters were
assessed by Spearman rank correlation. Univariable and
multivariable logistic regression analyses were used to ex-
amine associations between variables and worsening renal
function. To contrast prognostic accuracy, statistical com-
parison of receiver-operating characteristic curves was per-
formed. To compare different predictive values, we con-
structed areas under the receiver-operating characteristic
curve for sensitivity, specificity, positive predictive value and
negative predictive value. The best prognostic cutoff for
survival status was defined as the highest product of sensi-
tivity and specificity. Net reclassification improvement and
integrated discrimination improvement were performed
with biomarkers kept as dichotomous variables, as described
by Pencina et al. (20), where the categories of probability for
events are defined based on prognostication scheme of the
Heart Failure Survival Score (21). We calculated hazard
ratios (HRs) derived from the Cox regression analysis to
identify predictors of mortality and/or HF hospitalization
during follow-up. The independent effect of variables on
prognosis was calculated using a Cox multivariable regres-
sion analysis, incorporating covariates with p values 0.10
in the univariable analysis. To avoid colinearity effects, due
to their extremely high correlation (r  0.80), serum
creatinine and eGFR, as well as BTP and cystatin C, were
not entered together in multivariate models. The cumulative
incidence of all-cause death or HF hospitalization was
estimated according to the Kaplan-Meier method, and the
log-rank statistic was used for comparisons. All p values
0.05 were accepted as statistically significant. Statistical
analysis was performed using SPSS version 15.0 (SPSS,
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Institute Inc., Cary, North Carolina).
Results
Among the 220 subjects with ADHF, the median plasma
BTP concentration was 0.97 mg/l (range 0.74 to 1.37 mg/l),
the median plasma cystatin C concentration was 1.15 mg/l
(range 0.90 to 1.59 mg/l), the median serum creatinine was
1.14 mg/dl (range 0.84 to 1.45 mg/dl), the median eGFR
was 64 ml/min/1.73 m2 (range 45 to 78 ml/min/1.73 m2),
and the median BUN was 24 mg/dl (range 18 to 34 mg/dl).
Plasma BTP concentration was positively correlated with
cystatin C concentration (r  0.86; p  0.001). Both
plasma BTP and cystatin C concentrations were positively
correlated with serum creatinine, BUN, age, New York
Heart Association functional class, N-terminal pro–B-type
natriuretic peptide (NT-proBNP), uric acid, troponin T,
and C-reactive protein, whereas both were negatively cor-
related with eGFR, serum albumin, and hemoglobin. BTP
and cystatin C concentrations were not correlated with body
mass index or left ventricular ejection fraction (Table 1).
Worsening renal function during hospital admission oc-
curred in 66 patients (30%). Patients with worsening renal
function and those without worsening renal function pre-
sented similar plasma BTP (1.03 mg/l [range 0.75 to 1.44
mg/l] vs. 0.96 mg/l [range 0.71 to 1.35 mg/l]; p  0.35),
cystatin C (1.12 mg/l [range 0.87 to 1.71 mg/l] vs. 1.19
mg/l [range 0.90 to 1.54 mg/l]; p  0.73), creatinine (1.11
mg/l [range 0.84 to 1.49 mg/l] vs. 1.15 mg/l [range 0.85 to
1.44 mg/l]; p 0.83), eGFR (64 ml/min/1.73 m2 [range 44
to 77 ml/min/1.73 m2] vs. 64 ml/min/1.73 m2 [range 45 to
9 ml/min/1.73 m2]; p  0.77), and BUN (24 mg/l [range
21 to 34 mg/l] vs. 24 mg/l [range 17 to 34 mg/l]; p 0.32).
In a multivariable logistical regression model, only a history
of coronary artery bypass surgery (odds ratio: 3.87, 95%
confidence interval [CI]: 1.120 to 12.5; p  0.023) and
Correlations Between -Trace Protein, CystatinTable 1 Correlations Between -Trace Prote
-Tr
Variables R
Age, yrs 0.32
Albumin, g/dl 0.13
Body mass index, kg/m2 0.06
C-reactive protein, mg/dl 0.16
Creatinine, mg/dl 0.70
Cystatin C, mg/l 0.86
eGFR, ml/min/1.73 m2 0.71
Hemoglobin, g/dl 0.38
Left ventricular ejection fraction 0.07
NYHA functional class (I–IV) 0.22
Plasma NT-proBNP, pg/ml 0.29
Troponin T, ng/dl 0.13
Blood urea nitrogen, mg/dl 0.67
Uric acid, mg/dl 0.40eGFR  estimated glomerular filtration rate; NT-proBNP  N-terminal pro–B-female (odds ratio: 2.07, 95% CI: 1.13 to 3.78; p  0.019)
ere significantly associated with worsening of renal function.
During the study period (median 500 days; interquar-
ile range 231 to 796 days), a total of 116 patients (53%)
xperienced adverse clinical events: 62 patients died and
6 patients were readmitted to the hospital because of
F decompensation. The distribution of characteristics
nd laboratory parameters according to the occurrence of
dverse clinical events is shown in Tables 2 and 3.
atients who experienced adverse clinical events during
ollow-up were more likely to be older and more likely to
ave had previous HF and poorer functional status, to
eed more frequent in-hospital inotropic support, and to
ave a higher rate of worsening renal function during the
ospital admission.
Those who experienced adverse clinical events had higher
lasma BTP concentration (1.04 mg/l [range 0.80 to 1.49
g/l] vs. 0.88 mg/l [range 0.68 to 1.17 mg/l], p  0.003)
Fig. 1A) and cystatin C concentration (1.29 mg/l [range
.00 to 1.71 mg/l] vs. 1.03 mg/l [range 0.86 to 1.43 mg/l],
 0.001) (Fig. 1B) compared with those with no adverse
clinical events. Serum creatinine, BUN, NT-proBNP, and
troponin T levels were also higher among patients who
experienced adverse clinical events, whereas the glucose level
and eGFR were lower among these patients.
Tertile analyses of BTP and cystatin C concentrations
examined as a function of adverse clinical event rates
revealed that there was a graded increase in mortality and/or
HF hospitalization with increasing concentrations of these
markers (Fig. 2).
To define the optimal prognostic accuracy of BTP values
regarding survival of adverse clinical events, we performed
receiving-operating characteristic curve analyses. For com-
parison, the same receiving-operating characteristic curve
analyses were performed with cystatin C, eGFR, and BUN.
As detailed in Table 4, BTP and cystatin C had comparable
d Clinical Variablesystatin C, and Clinical Variables
otein Cystatin C
p Value R p Value
0.001 0.29 0.001
0.05 0.19 0.004
0.42 0.09 0.23
0.026 0.21 0.003
0.001 0.73 0.001
0.001 — —
0.001 0.76 0.001
0.001 0.33 0.001
0.28 0.04 0.56
0.001 0.25 0.001
0.001 0.37 0.001
0.06 0.16 0.02
0.001 0.72 0.001
0.001 0.45 0.001C, anin, C
ace Prtype natriuretic peptide; NYHA  New York Heart Association.
w
0
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istics that appeared similar, if not slightly superior, to the
more conventional measures of renal function. The net
reclassification improvement with the addition of cystatin C
Study Population Clinical Characteristicsas a Function f Mortality and/or HF HospitalizaTable 2 Study Populatio Clinical Characteras a Function of Mortality and/or H
Variables
Age, yrs
Male
Body mass index, kg/m2
Systolic blood pressure, mm Hg
Heart rate, beats/min
Left ventricular ejection fraction
NYHA functional class III–IV
Previous HF
Previous coronary artery bypass graft
Previous percutaneous coronary intervention
Ischemic cause of HF
Diabetes mellitus
Hypertension
Hyperlipidemia
Current smoking
Peripheral artery disease
Atrial fibrillation/flutter
Branch block
Previous ST-segment elevation myocardial infarction
Previous stroke
Anemia
Chronic obstructive pulmonary disease
In-hospital inotropic use
Worsening of renal function
Treatment at discharge
Beta-blocker
ACE inhibitors/ARB
Statin
Aldosterone antagonist
Loop diuretic
Data are expressed as mean  SD or n (%).
ACE  angiotensin-converting enzyme; ARB  angiotensin-receptor
Baseline Laboratory Parameters as a Function oTable 3 Baseline Laboratory Parameters as
Variable
Events
(n  116)
Hemoglobin, g/dl 12.1 (10.9–13.6
Leukocytes 8,350 (6,735–11
Glucose, mg/dl 163 (114–214
Creatinine, mg/dl 1.18 (0.92–1.59
eGFR, ml/min/1.73 m2 62 (43–74)
Blood urea nitrogen, mg/dl 27 (20–37)
Albumin, g/dl 3.9 0.4
Sodium, mEq/l 137 5
Uric acid, mg/dl 7.7 2.9
C-reactive protein, mg/dl 1.30 (0.60–4.02
Troponin T, ng/ml 0.018 (0.010–0.0
Plasma NT-proBNP, pg/ml 4,010 (2,021–7,7Data are expressed as median (quartiles) or mean  SD.
Abbreviations as in Table 1.to eGFR was 0.28 (95% CI: 0.13 to 0.43, p  0.002),
hereas the integrated discrimination improvement was
.05 (95% CI: 0.02 to 0.08, p  0.001). The probability
of correctly predicting death and/or HF readmission
spitalization
Events
(n  116)
No Events
(n  104) p Value
75 10 69 13 0.002
67 (57.3) 49 (47.2) 0.15
29 5 29 4 0.65
150 37 153 34 0.69
100 28 100 34 0.96
45 17 48 16 0.26
53 (45.3) 12 (11.7) 0.001
85 (72.6) 50 (48.5) 0.001
6 (5.1) 7 (6.8) 0.60
32 (27.4) 20 (19.4) 0.17
40 (34.2) 32 (31.1) 0.62
66 (56.4) 48 (46.6) 0.15
95 (81.2) 85 (82.5) 0.80
50 (42.7) 43 (41.7) 0.88
14 (12) 17 (16.5) 0.33
11 (9.4) 6 (5.8) 0.32
72 (61.5) 54 (52.4) 0.17
39 (34.2) 30 (29.1) 0.42
36 (30.8) 21 (20.4) 0.08
15 (12.8) 13 (12.6) 0.96
60 (51.3) 43 (41.7) 0.16
31 (26.5) 22 (21.4) 0.37
20 (17.1) 3 (2.9) 0.001
43 (37) 23 (22) 0.016
58 (55.2) 74 (72.5) 0.01
88 (83.8) 87 (85.3) 0.77
58 (55.2) 55 (53.9) 0.85
34 (32.4) 39 (38.2) 0.38
100 (95.2) 91 (89.2) 0.11
r; HF  heart failure; NYHA  New York Heart Association.
rtality and/or HF Hospitalizationnction of Mortality and/or HF Hospitalization
No Events
(n  104) p Value
12.3 (11.4–14.6) 0.09
8,050 (6,370–9,590) 0.08
131 (109–188) 0.03
1.02 (0.82–1.37) 0.02
66 (48–80) 0.03
22 (16–29) 0.001
4.0 0.4 0.57
138 4 0.08
7.4 2.2 0.29
0.90 (0.40–2.20) 0.11
0.010 (0.010–0.030) 0.008
2,502 (1,291–5,357) 0.006tionistics
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February 15, 2011:849–58 -Trace Protein, Cystatin C, and Acute Heart Failurewhen cystatin C was added to eGFR was particularly
reflected in the percentage of nonevents correctly reclas-
sified (44%), whereas the percentage of events reclassified
was 16%. Compared with cystatin C, BTP had a net
reclassification improvement of 0, with an integrated
discrimination improvement of 0.00008; compared with
cystatin C, BTP had a 0% reclassification of either events
or nonevents, indicating that BTP offered information
comparable to that of cystatin C.
In univariable Cox regression analysis, all measures of
Figure 1 -Trace Protein and Cystatin C Concentrations
as a Function of Mortality and/or HF Hospitalization
Box plots of the concentrations of -trace protein (A) and cystatin C (B) in
patients who died and/or were hospitalized for heart failure (HF) and those
who did not experience adverse clinical events. The bottom and top whiskers
indicate the 5th and 95th percentile levels; the lower and upper boundaries of
the boxes, the 25th and 75th percentile levels; and the horizontal line within
the box, the median level.kidney function were associated with a higher risk of adverseclinical events (Table 5). However, after adjusting for
confounding factors in the multivariable Cox regression
models, only BTP and cystatin C concentrations remained
as significant predictors of adverse events, whereas creati-
nine, eGFR, and BUN were no longer significant (Table 5).
This remained the case when measurements of renal func-
ion were evaluated as dichotomous variables in multivariate
ox regression models: BTP and cystatin C were significant
redictors of mortality and/or HF readmission (HR: 1.54, 95%
I: 1.10 to 2.38; p 0.02 for BTP0.96 mg/l and HR: 1.73,
95% CI: 1.15 to 2.62; p  0.009 for cystatin C 1.05 mg/l),
ut creatinine, eGFR, and BUN were not (p  0.2). Further-
more, when BTP and cystatin C were adjusted for other
conventional measures of kidney function, both remained
associated with a higher risk of adverse events (log10 BTP, HR:
3.01, 95% CI: 1.08 to 7.87, p  0.033 and log10 cystatin C,
HR: 3.56, 95% CI: 1.22 to 9.35, p  0.018).
As shown in the Kaplan-Meier survival analyses, in-
creased BTP concentration (0.96 mg/l) and elevated
cystatin C concentration (1.05 mg/l) were associated with
an increased risk of adverse clinical events (Fig. 3) (log-rank
test, p  0.05). In stratified analyses of patients with an
eGFR 60 ml/min/1.73 m2 (n  146), increased BTP and
ystatin C concentrations were also found to be associ-
ted with a higher mortality and/or HF hospitalization
isk (Fig. 4) (log-rank test, p  0.05).
iscussion
he importance of parameters of renal function in ADHF
s considerable. Indeed, kidney dysfunction represents one
f the most dominant variables for predicting adverse
utcome in patients with ADHF (22,23). Although pow-
rfully predictive of adverse outcome, conventional tests for
Figure 2 Mortality and/or HF Hospitalization as a
Function of BTP and Cystatin C Tertiles
Rates of mortality and/or heart failure (HF) hospitalization were significantly
higher with increasing concentrations of both -trace protein (BTP) (p  0.008)
and cystatin C (p  0.001).
PV  ne
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-Trace Protein, Cystatin C, and Acute Heart Failure February 15, 2011:849–58kidney dysfunction such as creatinine, eGFR, and BUN all
have potential limitations (2–4); thus, characterization of
newer markers of renal dysfunction for application in
patients with ADHF is of considerable significance.
In this study, we examined novel markers of renal
dysfunction, BTP, and cystatin C and compared them with
conventional measures of renal function for their ability to
predict adverse outcome. Neither BTP nor cystatin C at
presentation (or other measures of renal function) predicted
the onset of renal dysfunction after presentation with
ADHF. This suggests that baseline renal function may be
less important for predicting subsequent worsening in glo-
merular filtration rate (GFR) than are the various clinical
and therapeutic insults that occur in patients with ADHF
that may lead to such a decline. On the other hand,
consistent with previous reports (5–13), we found cystatin C
to independently predict death/HF hospitalization with
greater accuracy than creatinine, eGFR, or BUN; moreover,
BTP performed comparably to cystatin C for this indica-
tion. Of special note, among patients with an eGFR 60
Performance of Measures of Renal Function and NT-proBNP forredictio of 1-Year Mortality a d/or HF Hospitalization in PatientsTable 4 Performance of M asures of Renal Functi and NT-prPrediction of 1-Year Mortality and/or HF Hospitalizatio
Variables AUC 95% CI Cutoff
-trace protein, mg/dl 0.62 0.55–0.68 0.96
Cystatin C, mg/dl 0.63 0.56–0.69 1.05
Creatinine, mg/dl 0.58 0.52–0.65 1.07
eGFR, ml/min/1.73 m2 0.57 0.50–0.64 72
Blood urea nitrogen, mg/dl 0.60 0.53–0.66 25
Plasma NT-proBNP, pg/ml 0.60 0.53–0.67 3,041
The p values shown are for comparison among -trace protein and other variables.
ADHF  acutely destabilized heart failure; AUC area under the curve; CI confidence interval; N
Cox Regression Risk Analysis for Prediction of Mortality and/or HFTable 5 Cox Regression Risk Analysis for Prediction of Mortali
Un
Variables Hazard Rat
Age,  yr 1.03 (1.01–1.
Left ventricular ejection fraction 0.99 (0.98–1.
NYHA functional class III–IV 2.91 (2.01–4.
Diabetes mellitus 1.39 (0.96–2.
Previous HF 1.94 (1.29–2.
Previous ST-segment elevation myocardial infarction 1.56 (1.05–2.
In-hospital inotropic use 2.43 (1.50–4.
Log10 glucose 2.71 (1.05–7.
Sodium,  mEq/l 0.96 (0.93–1.
Log10 leukocytes 5.26 (1.40–19
Log10 plasma NT-proBNP 1.75 (1.18–2.
Log10 troponin T 1.51 (1.09–2.
Worsening renal function 1.52 (1.04–2.
Log10 -trace protein 3.30 (1.39–7.
Log10 cystatin C 4.57 (1.66–12
Log10 creatinine 4.21 (1.34–11
Log10 eGFR 0.47 (0.34–0.
Log10 blood urea nitrogen 2.58 (1.05–8.Log10 -trace protein, log10 cystatin C, log10 creatinine, and log10 eGFR were all tested separately and m
Abbreviations as in Tables 1 and 2.ml/min (an area of weakness for serum creatinine and
eGFR), we found that increased concentrations of both
BTP and cystatin C were still associated with significantly
higher risk of adverse clinical events. To the best of our
knowledge, this is the first study to describe the prognostic
usefulness of BTP in ADHF.
Over the past years, kidney dysfunction, including mild
and moderate chronic kidney disease, has become increas-
ingly recognized as an independent risk factor for morbidity
and mortality in patients with HF (22–28). A recent
meta-analysis (29) showed that the majority of patients with
HF had some degree of renal impairment, and these
patients represent a high-risk group with an approximately
50% increased relative mortality risk compared with patients
with normal kidney function. Because serum creatinine,
eGFR equations, and BUN are insensitive to mild decre-
ments in renal function (2–4), the detection of mild kidney
dysfunction in routine clinical practice remains challenging.
It has been suggested that BTP and cystatin C concentra-
tions are more sensitive for the detection of mild decrements
h ADHFfor
Patients With ADHF
Sensitivity Specificity PPV NPV p Value
0.61 0.60 0.66 0.55
0.72 0.55 0.64 0.63 0.73
0.64 0.54 0.61 0.57 0.34
0.65 0.44 0.57 0.53 0.26
0.53 0.65 0.63 0.55 0.71
0.62 0.57 0.62 0.57 0.70
gative predictive value; PPV  positive predictive value; other abbreviations as in Tables 1 and 2.
pitalizationd/or HF Hospitalization
te Analysis Multivariate Analysis
p Value Hazard Ratio p Value
0.001 1.04 (1.01–1.06) 0.001
0.06 0.98 (0.97–0.99) 0.023
0.001 2.11 (1.48–3.01) 0.001
0.08 — 0.51
0.001 — 0.14
0.03 — 0.19
0.001 2.16 (1.26–3.72) 0.005
0.04 — 0.33
0.09 — 0.11
0.014 8.58 (2.21–33.3) 0.002
0.006 — 0.47
0.014 2.66 (1.51–4.71) 0.001
0.031 — 0.14
0.007 3.19 (1.15–8.92) 0.026
0.003 4.20 (1.31–13.3) 0.015
0.006 — 0.14
0.007 — 0.30
0.009 — 0.26WitoBNP
n inHosty an
ivaria
io
05)
01)
22)
00)
91)
32)
01)
02)
01)
.8)
59)
11)
21)
84)
.6)
.8)
85)
8)ultivariable hazard ratios and p values for other variables shown from the -trace protein model.
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found both BTP and cystatin C to be independently
superior to standard measures of renal function for predict-
ing death and/or HF hospitalization. Given the reported
value of conventional measures of renal function for prog-
nostication in patients with ADHF (22,23), our findings are
of significance.
BTP is a low-molecular weight glycoprotein, belonging
to the lipocalin protein family, with a molecular weight of
22 to 29 kDa depending on the degree of glycosylation
(32,33). BTP is synthesized in the central nervous system,
male genital organs, and heart and is secreted into the
cerebrospinal fluid, seminal plasma, and plasma, respectively
Figure 3 Mortality and/or Heart Failure Hospitalization in the E
Kaplan-Meier survival curves for mortality and/or heart failure hospitalization acco(34–36). Hoffmann et al. (33) showed that “brain type”BTP is absent in serum and urine (because it is cleared by
the liver via specific hepatic glycoprotein receptors), whereas
sialyzed glycoforms are protected against hepatic metabo-
lism and are eliminated via glomerular filtration, allowing
for sensitive estimation of renal function.
As mentioned previously, plasma BTP concentration
appears superior to standard means of renal function
estimation for the detection of mild decrements of GFR.
Thus, our results might indicate that the risk of adverse
events attributable to kidney disease is not completely
captured by estimates of kidney function routinely used in
clinical practice. On the other hand, BTP has also been
implicated in numerous other physiologic and pathologic
Population
o -trace protein (A) and cystatin C (B) concentrations.ntire
rding tprocesses including inflammatory responses (37), endo-
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sensitivity (40), and systemic arterial hypertension (41).
We therefore cannot exclude the possibility that circu-
lating BTP concentrations reflect (directly or indirectly)
pathophysiologic processes pivotal to HF progression.
Cystatin C is a low-molecular weight protein (13 kDa)
that is released at a constant rate and expressed in all
nucleated cells (42). It has multiple biological functions,
including controlling extracellular proteolysis via inhibition
of cysteine peptidases (especially cathepsins B, H, L, and S)
(43), modulation of the immune system (44), exertion of
Figure 4 Mortality and/or Heart Failure Hospitalization in Patie
Kaplan-Meier survival curves for mortality and/or heart failure hospitalization acco
in patients with an estimated glomerular filtration rate 60 ml/min/1.73 m2.antibacterial and antiviral activities, and modification of thebody’s response to brain injury. Cystatin C is freely filtrated
in the glomerulus and subsequently absorbed in the renal
tubules where it is fully degraded locally, without re-
entering the bloodstream. No active tubular secretion or
significant extrarenal elimination occurs (45,46). Therefore,
plasma cystatin C concentration is mainly dependent on the
GFR. Although several previous studies have shown that
plasma cystatin C concentration predicts adverse clinical
outcomes across a wide spectrum of patients including those
with HF (5–13), it also remains unclear, however, whether
the association with adverse outcomes is due to cystatin C
ithout Advance Kidney Dysfunction
o -trace protein (A) and cystatin C (B) concentrationsnts W
rding tbeing a more precise measure of kidney function or whether
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independent of the GFR. Importantly, cystatin C has not
been previously compared with BTP as a prognostic risk
factor, so the present study adds to the existing literature by
demonstrating that BTP is at least comparable to cystatin C
for predicting adverse clinical events in hospitalized patients
with ADHF.
Study limitations. The limitations of our study are similar
to those of any single-center prospective, observational
study. The small sample size and relatively small number of
patients included in each group also make it difficult to draw
firm conclusions. In this study, we included unselected
hospitalized patients with ADHF due to both systolic and
nonsystolic mechanisms, so the validity of our findings in
selected HF populations remains to be established. In
addition, the presence of unmeasured variables such as
activity of coronary ischemia, diastolic abnormalities, and
severity of valvular heart disease were not factored into our
multivariable Cox regression analyses for prediction of poor
outcomes. For the prediction of outcomes, the number of
covariates included in multivariable models was 1 for each
10 events. Therefore, it remains possible that the models
were overadjusted, and consequently our results could fail to
be replicated in future samples. In our study cohort, we
found that increased plasma NT-proBNP concentration did
not predict adverse clinical events beyond cystatin C and
BTP. However, because several previous studies have dem-
onstrated that NT-proBNP and cystatin C concentrations
offered complementary prognostic value in this clinical
setting (5,11,12), we cannot exclude that our results may
represent a false-negative (type II) error due to overadjust-
ment of covariates in the context of a relatively small
number of subjects with ADHF. Furthermore, we also
found that worsening of renal function was not associated
with adverse clinical events after adjustment for baseline
clinical and biochemical risk factors. This likely reflects the
dominance of baseline novel renal function parameters over
a worsening of renal function definition based on an
absolute increase in serum creatinine during hospitalization.
Last, we do not have follow-up (post-treatment) values for
measures of renal function; such follow-up values would be
expected to provide further prognostic information about
our patients.
Conclusions
In patients with ADHF, BTP and cystatin C appear to add
comparable and significant prognostic value and were supe-
rior to creatinine, eGFR, and BUN, each a well-established
prognostic variable in this context.
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